Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosa

Project description

Synthetic vaccines against antibiotic-resistant Pseudomonas aeruginosa

Pseudomonas aeruginosa is a gram-negative, rod-shaped bacterium that causes disease. This multidrug-resistant pathogen has advanced antibiotic resistance mechanisms, forms biofilms and is associated with hospital-acquired infections such as ventilator-associated pneumonia and sepsis syndromes. Pseudomonas aeruginosa biofilm's matrix is composed of alginate and two essential types of sugars (exopolysacharides) named PSL and PEL. The EU-funded PAVax project will explore and exploit these saccharides to generate novel targeted vaccines. The consortium merges the complementary expertise of its academic and industrial partners to achieve its ambitious goals. Thanks to the partners' joint effort and collaboration, the project's four early-stage researchers will be trained at the highest professional level.

Objective

PAVax is a network that will train 4 early-stage researchers (ESRs) on the conception of new synthetic vaccines to combat the antibiotic resistant bacterium Pseudomionas aeruginosa (PA), for which there currently is no adequate vaccine available. This consortium will explore and exploit the use of PA-exopolysaccharides that play a key role in biofilm formation that protects the bacterium from its environment: alginate, Psl and Pel. We will exploit these saccharides to generate novel vaccines targeting these exposed polysaccharides. Next to the isolation of these polysaccharides from the bacteria, we will employ synthetic chemistry to deliver well-defined fragments of these polysaccharides. These will be used to map the interactions of the saccharides with antibodies to inform on the structure of the optimal epitope. We will conjugate the (synthetic) fragments to newly discovered PA proteins to generate conjugate vaccines targeting multiple PA entities. The consortium is formed by an academic partner, Leiden University (NL) and an industrial partner, GSK Vaccines, Siena (IT), harnessing the complementary expertise of both partners to achieve the ambitious goals set. The close collaboration between the two partners will ensure training of the ESRs at the highest level and best synergy possible. The ESRs will receive intersectorial, international and interdisciplinary training in (synthetic) carbohydrate chemistry, vaccine design, protein chemistry and conjugation, biophysical interaction studies, and immunology. With the ever-growing awareness of the importance of carbohydrates in health and disease, and the continuous threat of multidrug resistant bacteria, the skill set acquired by the ESRs will prepare them to face the major scientific and societal challenges ahead and become important players in academic or industrial research in the future

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-ITN-2019

See all projects funded under this call

Coordinator

UNIVERSITEIT LEIDEN
Net EU contribution
€ 531 239,76
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 531 239,76

Participants (1)